Ligand-binding assays (LBAs) are the most common methods for detection of antidrug antibodies. LBAs offer high throughput as well as excellent sensitivity and specificity; however, they also have their limitations. With advances in instrumentation, approaches using LC-MS have emerged as an adjunct tool to overcome some of the challenges associated with conventional LBAs. The Alliance team shares perspectives on both platforms and the potential future of immunogenicity testing.
